Astrana Health, Inc. (ASTH)
| Market Cap | 1.93B +5.8% |
| Revenue (ttm) | 3.53B +56.7% |
| Net Income | 30.23M -13.6% |
| EPS | 0.61 -16.6% |
| Shares Out | 49.58M |
| PE Ratio | 64.01 |
| Forward PE | 27.12 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491,742 |
| Open | 38.26 |
| Previous Close | 38.26 |
| Day's Range | 38.25 - 39.75 |
| 52-Week Range | 18.08 - 39.93 |
| Beta | 0.99 |
| Analysts | Strong Buy |
| Price Target | 44.56 (+14.32%) |
| Earnings Date | May 7, 2026 |
About ASTH
Astrana Health, Inc., a healthcare management company, provides medical care services in the United States. The company operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans. Its physician network includes primary care physicians, specialist physicians and extenders, and hospitalists. The company serves patients prima... [Read more]
Financial Performance
In 2025, Astrana Health's revenue was $3.18 billion, an increase of 56.39% compared to the previous year's $2.03 billion. Earnings were $22.49 million, a decrease of -47.89%.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for ASTH stock is "Strong Buy." The 12-month stock price target is $44.56, which is an increase of 14.32% from the latest price.
News
Astrana Health price target raised to $47 from $38 at Truist
Truist raised the firm’s price target on Astrana Health (ASTH) to $47 from $38 and keeps a Buy rating on the shares. The firm is citing the company’s Q1 earnings…
Astrana Health management to meet with BTIG
Healthcare IT and Digital Health Analyst Larsen holds a meeting with management to be held in the Midwest region on May 20 hosted by BTIG.
Astrana Health Transcript: Bank of America Global Healthcare Conference 2026
Strong growth and successful integration of a major acquisition have driven operational and financial outperformance, with technology and AI streamlining care and administrative processes. Regulatory changes are expected to have limited impact, and Medicaid margins are projected to recover as rate adjustments align with member acuity.
Astrana Health, Inc. Announces Appointment of Interim National Medical Director
ALHAMBRA, Calif., May 12, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, technolo...
Astrana Health price target raised to $45 from $35 at TD Cowen
TD Cowen raised the firm’s price target on Astrana Health (ASTH) to $45 from $35 and keeps a Buy rating on the shares. The firm updated its model followng better…
Astrana Health partners with Physician Association of California
Astrana Health (ASTH) and The Physician Association of California, or PAC, a physician-centric, technology-enabled healthcare company, announced a collaboration to help independent primary care physic...
Physician Association of California and Astrana Health Launch Collaboration to Strengthen Independent Primary Care
Expands access to Astrana's Medicare ACO platform, powered by a unified AI-powered platform designed for independent physicians ALHAMBRA, Calif., May 11, 2026 /PRNewswire/ -- The Physician Association...
Astrana Health price target raised to $37 from $26 at Barclays
Barclays raised the firm’s price target on Astrana Health (ASTH) to $37 from $26 and keeps an Equal Weight rating on the shares.
Astrana Health price target raised to $41 from $30 at Needham
Needham analyst Matthew Shea raised the firm’s price target on Astrana Health (ASTH) to $41 from $30 and keeps a Buy rating on the shares.
Astrana Health price target raised to $45 from $40 at Baird
Baird raised the firm’s price target on Astrana Health (ASTH) to $45 from $40 and keeps an Outperform rating on the shares. The firm updated its model following results as…
Astrana Health reports Q1 adjusted EPS 74c, consensus 65c
Reports Q1 revenue $965.1M, consensus $948.42M. “We had a strong start to 2026, delivering disciplined growth, strong medical cost performance, continued operating leverage, and early performance from...
Astrana Health sees Q2 revenue $965M-$1B, consensus $973.68M
Sees Q2 adjusted EBITDA $65M-$70M.
Astrana Health sees FY26 revenue $3.8B-$4.1B, consensus $3.99B
Sees FY26 adjusted EBITDA $250M-$280M.
Astrana Health Earnings Call Transcript: Q1 2026
Q1 2026 saw 56% revenue and 82% adjusted EBITDA growth, with strong free cash flow and rapid deleveraging. Full risk contracts and AI-enabled efficiencies drove margin gains, while guidance for 2026 and 2027 remains robust amid favorable regulatory and market trends.
Astrana Health Earnings release: Q1 2026
Astrana Health released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Astrana Health Slides: Q1 2026
Astrana Health has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 7, 2026.
Astrana Health Quarterly report: Q1 2026
Astrana Health has published its Q1 2026 quarterly earnings report on May 7, 2026.
Astrana Health, Inc. Reports First Quarter 2026 Results
Company to Host Conference Call on Thursday, May 7, 2026, at 2:30 p.m. PT/5:30 p.m.
Astrana Health, Inc. Schedules 2026 First Quarter Financial Results Release and Conference Call
ALHAMBRA, Calif., April 21, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, techno...
Astrana Health Proxy statement: Proxy filing
Astrana Health filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Astrana Health Proxy statement: Proxy filing
Astrana Health filed a proxy statement on April 17, 2026, providing details for shareholder voting and corporate governance matters.
Astrana Health price target raised to $40 from $37 at Baird
Baird raised the firm’s price target on Astrana Health (ASTH) to $40 from $37 and keeps an Outperform rating on the shares. The firm updated its model as it becomes…
Astrana Health, Inc. to Participate in Upcoming Investor Conferences
ALHAMBRA, Calif., April 10, 2026 /PRNewswire/ -- Astrana Health, Inc. ("Astrana," and together with its subsidiaries and affiliated entities, the "Company") (NASDAQ: ASTH), a physician-centric, techno...
Astrana Health files automatic mixed securities shelf
06:11 EDT Astrana Health (ASTH) files automatic mixed securities shelf
Astrana Health price target raised to $38 from $37 at Truist
Truist analyst Jailendra Singh raised the firm’s price target on Astrana Health (ASTH) to $38 from $37 and keeps a Buy rating on the shares. The firm notes that the…